How oppositionality, inattention, and hyperactivity affect response to atomoxetine versus methylphenidate: A pooled meta-analysis

Journal of Attention Disorders

Volumn 16, Issue 4, 2012, Pages 314-324

  van Wyk, Gregory W ^a   Hazell, Philip L ^b   Kohn, Michael R ^c   Granger, Renee E ^a   Walton, Richard J ^a  

^a ELI LILLY AUSTRALIA PTY LTD   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

ADHD; Atomoxetine; Meta analysis; Methylphenidate; Oppositional defiant disorder

Indexed keywords

ATOMOXETINE; CENTRAL STIMULANT AGENT; METHYLPHENIDATE; PROPYLAMINE;

ADOLESCENT; ATTENTION DEFICIT DISORDER; CHILD; HUMAN; HYPERKINESIA; META ANALYSIS; REVIEW; TREATMENT OUTCOME;

ADOLESCENT; ATTENTION DEFICIT AND DISRUPTIVE BEHAVIOR DISORDERS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; HUMANS; HYPERKINESIS; METHYLPHENIDATE; PROPYLAMINES; TREATMENT OUTCOME;

EID: 84859577994     PISSN: 10870547     EISSN: 15571246     Source Type: Journal    
DOI: 10.1177/1087054710389989     Document Type: Review

References (36)

1. American Academy of Pediatrics. (2001). Subcommittee on attention-deficit/hyperactivity disorder and committee on quality improvement. Clinical practice guideline: Treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics, 108, 1033-1044.
2. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author.
3. Berlin, J. A., Laird, N. M., Sacks, H. S., & Chalmers, T. C. (1989). A comparison of statistical methods for combining event rates from clinical trials. Statistics in Medicine, 8, 141-151.
4. Biederman, J., Petty, C. R., Dolan, C., Hughes, S., Mick, E., Monuteaux, M. C., Faraone, S. V. (2008). The long-term longitudinal course of oppositional defiant disorder and conduct disorder in ADHD boys: Findings from a controlled 10-year prospective longitudinal follow-up study. Psychological Medicine, 38, 1027-1036.
5. Biederman, J., Petty, C. R., Monuteaux, M. C., Mick, E., Parcell, T., Westerberg, D, Faraone, S. V. (2008). The longitudinal course of comorbid oppositional defiant disorder in girls with attention-deficit/hyperactivity disorder: Findings from a controlled 5-year prospective longitudinal follow-up study. Journal of Developmental and Behavioral Pediatrics, 29, 501-507.
6. Biederman, J., Spencer, T. J., Newcorn, J. H., Gao, H., Milton, D. R., Feldman, P. D, White, M. M. (2007). Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: A meta-analysis of controlled clinical trial data. Psychopharmacology, 190, 31-41.
7. Bishop, Y., Fienberg, S., & Holland, P. (1975). Discrete multivariate analysis: Theory and practice. Cambridge, MA: MIT Press.
8. Cheng, J. Y., Chen, R. Y., Ko, J. S., & Ng, E. M. (2007). Efficacy and safety of atomoxetine for attention-deficit/hyperactivity disorder in children and adolescents-meta-analysis and metaregression analysis. Psychopharmacology, 194, 197-209.
9. DuPaul, G., Power, T., Anastopoulos, A., & Reid, R. (1998). ADHD Rating Scale-IV. Checklist, norms, and clinical interpretations. New York, NY: Guildford.
10. Faries, D. E., Yalcin, D., Harder, D., & Heiligenstein, J. H. (2001). Validation of the ADHD Rating Scale as a clinician-administered and scored instrument. Journal of Attention Disorders, 5, 107-115.
11. Gao, H., Zhao, Y., Levine, L., & Allen, A. (2006). Determining cut-points for clinically meaningful improvement: A receiver operating characteristic approach. Scientific Proceedings of the 53rd Annual Meeting of the American Academy of Child and Adolescent Psychiatry, Washington, DC.
12. Greenhill, L. L., Pliszka, S., Dulcan, M. K., Bernet, W., Arnold, V., Beitchman, J, Stock, S. (2002). Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child & Adolescent Psychiatry, 41, 26S-49S.
13. Guy, W. (1976). ECDEU assessment manual for psychopharmacology (Revised). Bethesda, MD: U.S. Department of Health, Education, and Welfare.
14. Hazell, P. L., Kohn, M. R., Dickson, R., Walton, R. J., Granger, R. E., & van Wyk, G. W. (in press). Core ADHD symptom improvement with atomoxetine versus methylphenidate: A direct comparison meta-analysis. Journal of Attention Disorders.
15. Jensen, P. S., Hinshaw, S. P., Kraemer, H. C., Lenora, N., Newcorn, J. H., Abikoff, H. B, Vitello, B. (2001). ADHD comorbidity findings from the MTA study: Comparing comorbid subgroups. Journal of the American Academy of Child & Adolescent Psychiatry, 40, 147-158.
16. Kemner, J. E., Starr, H. L., Ciccone, P. E., Hooper-Wood, C. G., & Crockett, R. S. (2005). Outcomes of OROS methylphenidatecompared with atomoxetine in children with ADHD: A multicenter, randomized prospective study. Advanced Therapeutics, 22, 498-512.
17. Kratochvil, C. J., Heiligenstein, J. H., Dittmann, R., Spencer, T. J., Biederman, J., Wernicke, J, Michelson, D. (2002). Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. Journal of the American Academy of Child & Adolescent Psychiatry, 41, 776-784.
18. Kratochvil, C. J., Wilens, T. E., Greenhill, L. L., Gao, H., Baker, K. D., Feldman, P. D, Gelowitz, D. L. (2006). Effects of long-term atomoxetine treatment for young children with attentiondeficit/ hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 45, 919-927.
19. Lagakos, S. W. (2006). The challenge of subgroup analyses- Reporting without distorting. New England Journal of Medicine, 354, 1667-1669.
20. Michelson, D., Allen, A. J., Busner, J., Casat, C., Dunn, D., Kratochvil, C, Harder, D. (2002). Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. American Journal of Psychiatry, 159, 1896-1901.
21. The MTA Cooperative Group. (1999). Moderators and mediators of treatment response for children with attention-deficit/ hyperactivity disorder: The Multimodal Treatment Study of children with attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56, 1088-1096.
22. Newcorn, J. H., Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J., Michelson, D. (2008). Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: Acute comparison and differential response. American Journal of Psychiatry, 165, 721-730.
23. Newcorn, J. H., Sutton, V. K., Weiss, M. D., & Sumner, C. R. (2009). Clinical responses to atomoxetine in attention-deficit/ hyperactivity disorder: The integrated data exploratory analysis (IDEA) study. Journal of the American Academy of Child & Adolescent Psychiatry, 48, 511-518.
24. Ollendick, T. H., Jarrett, M. A., Grills-Taquechel, A. E., Hovey, L. D., & Wolff, J. C. (2008). Comorbidity as a predictor and moderator of treatment outcome in youth with anxiety, affective, attention deficit/hyperactivity disorder, and oppositional/ conduct disorders. Clinical Psychology Review, 28, 1447-1471.
25. Pelham, W. E., Gnagy, E. M., Burrows-Maclean, L., Williams, A., Fabiano, G. A., Morrisey, S. M, Morse, G. D. (2001). Once-a-day concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics, 107, E105.
26. Petitti, D. B. (2001). Approaches to heterogeneity in meta-analysis. Statistics in Medicine, 20, 3625-3633.
27. Pliszka, S., & AACAP Work Group on Quality Issues. (2007). Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child & Adolescent Psychiatry, 46, 894-921.
28. Polanczyk, G., de Lima, M. S., Horta, B. L., Biederman, J., & Rohde, L. A. (2007). The worldwide prevalence of ADHD: A systematic review and meta-regression analysis. American Journal of Psychiatry, 164, 942-948.
29. Prasad, S., Harpin, V., Poole, L., Zeitlin, H., Jamdar, S., & Puvanendran, K. (2007). A multi-centre, randomised, openlabel study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/ hyperactivity disorder (ADHD). Current Medical Research and Opinion, 23, 379-394.
30. Sangal, R. B., Owens, J., Allen, A. J., Sutton, V., Schuh, K., & Kelsey, D. (2006). Effects of atomoxetine and methylphenidate on sleep in children with ADHD. Sleep, 29, 1573-1585.
31. Solanto, M. V., Pope-Boyd, S. A., Tryon, W. W., & Stepak, B. (2009). Social functioning in predominantly inattentive and combined subtypes of children with ADHD. Journal of Attention Disorders, 13, 27-35.
32. Spencer, T., Heiligenstein, J. H., Biederman, J., Faries, D. E., Kratochvil, C. J., Conners, C. K., Potter, W. Z. (2002). Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 63, 1140-1147.
33. Starr, H. L., & Kemner, J. (2005). Multicenter, randomized, openlabel study of OROS methylphenidate versus atomoxetine: Treatment outcomes in African-American children with ADHD. Journal of the National Medical Association, 97, 11S-16S.
34. Todd, R. D., Sitdhiraksa, N., Reich, W., Ji, T. H. C., Joyner, C. A., Heath, A. C, Neuman, R. J. (2002). Discrimination of DSM-IV and latent class attention-deficit/hyperactivity disorder subtypes by educational and cognitive performance in a population-based sample of child and adolescent twins. Journal of the American Academy of Child & Adolescent Psychiatry, 41, 820-828.
35. Wang, Y., Zheng, Y., Du, Y., Song, D. H., Shin, Y. J., Cho, S. C., Levine, L. R. (2007). Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: A randomized, double-blind comparison trial. Australian and New Zealand Journal of Psychiatry, 41, 222-230.
36. Wilens, T. E., Newcorn, J. H., Kratochvil, C. J., Gao, H., Thomason, C. K., Rogers, A. K, Levine, L. R. (2006). Longterm atomoxetine treatment in adolescents with attentiondeficit/ hyperactivity disorder. Journal of Pediatrics, 149, 112-119.